COMMUNIQUÉS West-GlobeNewswire

-
ProSomnus Contributes Two Scientific Abstracts for Presentation at SLEEP 2024, A Joint Meeting of the American Academy of Sleep Medicine and the Sleep Research Society
30/05/2024 -
Crossject announces publication of clinical data on ZEPIZURE ® in Neurology and Therapy
30/05/2024 -
Crossject annonce la publication de données cliniques sur ZEPIZURE® dans Neurology and Therapy
30/05/2024 -
Oculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to its Board of Directors and Scientific Advisory Board
30/05/2024 -
Oculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to its Board of Directors and Scientific Advisory Board
30/05/2024 -
Bayer and Burning Rock collaborate to increase patient access to precision cancer medicines
30/05/2024 -
Curium annonce les premieres doses commerciales en France de PYLCLARI® - un traceur PET innovant 18F-PSMA indique dans le cancer de la prostate
30/05/2024 -
Curium Announces First Commercial Doses in France of Pylclari® – an Innovative 18F-Psma Pet Tracer Indicated in Patients With Prostate Cancer
30/05/2024 -
Green Bioactives Reports Remarkable Cognitive Benefits of its Newly Launched Memory-boosting Nutraceutical Product, GBL-Memory¹
30/05/2024 -
Nxera Pharma to Receive $4.6 Million in Milestone Payments from Centessa Pharmaceuticals
30/05/2024 -
Samsung Bioepis to Present Post-hoc Analysis of Phase 3 Study for EPYSQLI™ (SB12; Eculizumab Biosimilar), at the European Hematology Association (EHA) Congress 2024
30/05/2024 -
Statement of total voting rights and shares forming the company’s share capital as of May 13, 2024
30/05/2024 -
Information relative au nombre total de droits de vote et d’actions composant le capital social au 13 mai 2024
30/05/2024 -
Combined General Meeting of June 20, 2024 - Availability of the preparatory documents
30/05/2024 -
Assemblée Générale Mixte du 20 juin 2024 - Modalités de mise à disposition des documents préparatoires
30/05/2024 -
Nxera Pharma and PrecisionLife Expand Strategic R&D Partnership into New Therapeutic Area
30/05/2024 -
Merus N.V. annonce une offre publique de souscription d’actions ordinaires
30/05/2024 -
Nicox annonce le lancement d’une augmentation de capital avec maintien du droit préférentiel de souscription sous forme d’ABSA d’un montant maximum d’environ 3,8 millions d’euros
30/05/2024 -
Merus Announces Pricing of Upsized Public Offering of Common Shares
30/05/2024
Pages